Key statistics
On Friday, Liquidia Corp (LQDA:NAQ) closed at 11.03, 82.01% above the 52 week low of 6.06 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.84 |
---|---|
High | 11.06 |
Low | 10.63 |
Bid | 10.07 |
Offer | 11.05 |
Previous close | 10.83 |
Average volume | 698.30k |
---|---|
Shares outstanding | 84.00m |
Free float | 67.63m |
P/E (TTM) | -- |
Market cap | 926.51m USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
- Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
- United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
- Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
- Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
- Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
- Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
- Liquidia to Present at Upcoming Investor Conferences
- Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
- U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
More ▼